Postmarket research
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.
Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
While the Danish drugmaker’s Tresiba (insulin degludec) didn’t fare as well as hoped in the head-to-head trial, Novo Nordisk was quick to point out that Tresiba showed an overall lower risk of hypoglycemia compared to Toujeo.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
PRESS RELEASES